Thesis
Selinexor's mixed SENTRY readout opens a narrow sNDA path in myelofibrosis, but survival hinges on an immediate capital raise and FDA's tolerance for a split primary endpoint
Selinexor is an XPO1 inhibitor being developed as add-on to ruxolitinib in JAKi-naïve myelofibrosis patients who achieved spleen but not symptom response in the Phase 3 SENTRY trial. The thesis resolves on whether FDA accepts a split co-primary outcome — SVR35 met, Abs-TSS missed — as the basis for an sNDA filing, supported by a compelling OS hazard ratio of 0.43. The regulatory precedent for approving a myelofibrosis combination on splenic response alone without symptom benefit is unestablished, and pacritinib and fedratinib already occupy second-line JAK inhibitor space, limiting commercial headroom even in a favorable scenario.
Focus
FDA Engagement on SENTRY sNDA Filing Plan
H2 2026
Bull
FDA signals willingness to accept the SVR35 result — supported by the compelling overall survival hazard ratio of 0.43 and VAF reduction data — and provides a clear sNDA submission pathway, potentially with an agreed filing package by end of 2026. This outcome would validate the myelofibrosis program as a near-term approval opportunity, materially re-rate the pipeline, and create a credible commercial story that supports further capital formation.
Bear
FDA indicates that a split co-primary endpoint result is insufficient for approval without an additional confirmatory trial or a reanalysis that addresses the failed Abs-TSS endpoint, effectively closing the sNDA path on current data. The most likely failure modes are agency insistence on both co-primaries being met per pre-specified statistical criteria and skepticism that the survival signal — based on limited events and a wide confidence interval touching 1.00 — is robust enough to substitute for the missed symptom endpoint.
Unlock the full thesis for KPTI.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.